Research article
Limitations to antiarrhythmic drug use in patients with atrial fibrillation
Karin H. Humphries, Charles R. Kerr, Michael Steinbuch, Paul Dorian and ; for The Canadian Registry of Atrial Fibrillation (CARAF) Investigators
CMAJ September 28, 2004 171 (7) 741-745; DOI: https://doi.org/10.1503/cmaj.1031277
Karin H. Humphries
Charles R. Kerr
Michael Steinbuch
In this issue
Article tools
Respond to this article
Limitations to antiarrhythmic drug use in patients with atrial fibrillation
Karin H. Humphries, Charles R. Kerr, Michael Steinbuch, Paul Dorian
CMAJ Sep 2004, 171 (7) 741-745; DOI: 10.1503/cmaj.1031277
Jump to section
Related Articles
Cited By...
- Docosahexaenoic Acid, but Not Eicosapentaenoic Acid, Supplementation Reduces Vulnerability to Atrial Fibrillation
- Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
- Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?